Cell-free fetal nucleic acids circulating in the blood of pregnant women afford the opportunity for early, noninvasive prenatal genetic testing. The predominance of admixed maternal genetic material in circulation demands innovative means for identification and analysis of cell-free fetal DNA and RNA. Techniques using polymerase chain reaction, mass spectrometry, and sequencing have been developed for the purposes of detecting fetal-specific sequences, such as paternally inherited or de novo mutations, or determining allelic balance or chromosome dosage. Clinical applications of these methods include fetal sex determination and blood group typing, which are currently available commercially although not offered routinely in the United States. Other uses of cell-free fetal DNA and RNA being explored are the detection of single-gene disorders, chromosomal abnormalities, and inheritance of parental polymorphisms across the whole fetal genome. The concentration of cell-free fetal DNA may also provide predictive capabilities for pregnancy-associated complications. The roles that cell-free fetal nucleic acid testing assume in the existing framework of prenatal screening and invasive diagnostic testing will depend on factors such as costs, clinical validity and utility, and perceived benefit-risk ratios for different applications. As cell-free fetal DNA and RNA testing continues to be developed and translated, significant ethical, legal, and social questions will arise that will need to be addressed by those with a stake in the use of this technology.
The passage of nucleated cells from fetal to maternal circulation was first noted by Walknowska et al 1 in 1969 , and potential applications and limitations of fetal cells for prenatal testing have since been well characterized. Although the genetic material derived from these cells theoretically provides a noninvasive means for prenatal testing, circulating fetal cells are scarce, and thus costly and time-consuming to isolate from a sample of maternal blood. [2] [3] [4] Universal cell markers that would allow separation and enrichment of nucleated fetal cells have yet to be discovered, precluding the use of these methods to obtain robust, reproducible results. 5 In 1997, the discovery of fragmented, cell-free fetal DNA circulating in maternal plasma and serum by Lo et al afforded a potential alternative to isolation of rare fetal cells for noninvasive testing. 6 Originating in trophoblast cells lining the placental intervillous space, fetal DNA fragments are released into maternal circulation after trophoblast degradation; apoptosis of fetal cells circulating in maternal blood may provide a minor source of cell-free fetal DNA. [7] [8] [9] Soon after this finding, the presence of placentaderived mRNA in maternal blood was also observed as a third source of fetal genetic material in maternal circulation. 10 Cell-free fetal DNA can be detected in maternal circulation as early as 5 weeks of gestational age and persists throughout pregnancy. 11 The transfer of cellfree fetal DNA to maternal blood is detectable in all pregnancies. 12 Due to its mean half-life of 16.3 minutes, cell-free fetal DNA is cleared from circulation within a matter of hours after delivery, and thus previous pregnancies do not confound identification and analysis of fetal DNA from a current pregnancy. 13 As expected, cell-free DNA in maternal circulation can be of either maternal or fetal origin, and the concentration of cellfree fetal DNA relative to total DNA ranges from 3.4% to 6.2%, or 25.4 to 292.2 genome equivalents per milliliter of maternal blood.
14 Potentially due to its instability or variable transcription throughout development, cell-free fetal mRNA can only be identified in 22% of first-and second-trimester pregnancies and 63% of third-trimester pregnancies. 10 Both fetal DNA and RNA may be stored in dried maternal blood spots for weeks after collection. 15, 16 Despite these qualities of cell-free fetal nucleic acids and particularly cell-free fetal DNA, their application in noninvasive prenatal testing has been hindered by the significant challenge of differentiating genetic material of the fetus from maternal genetic material. Namely, as the fetus has inherited one-half of its genetic information from its mother, the isolation of DNA or RNA fragments of fetal origin requires pinpointing information or features of these nucleic acids that distinguish them from their maternal counterparts.
The usefulness of fetal-specific sequences in maternal blood, including paternally inherited alleles or de novo mutations, is being explored with respect to sex determination, blood group and human leukocyte antigen (HLA) typing, and detection or exclusion of single-gene disorders or inheritance of other polymorphisms. For the purpose of aneuploidy detection, the ratio of concentrations of heterozygous alleles or sequences specific to particular chromosomes may be utilized. Epigenetic signatures of the fetus or mRNA species originating exclusively from the placenta may serve as alternative diagnostic tools by differentiating between fetal and maternal genetic material. 17, 18 Most recently, a map of the entire fetal genome has been constructed by coupling the search for particular alleles 
Determining Fetal Sex
For pregnancies medically indicated for prenatal sex testing, currently recommended invasive diagnostic procedures include chorionic villus sampling between 10 and 12 gestational weeks or amniocentesis between 15 and 20 weeks, each of which is followed by karyotyping resulting in essentially 100% accuracy in sex determination. 21 Sex can also be determined through ultrasonography with greater than 99% accuracy by a gestational age of 14 weeks. 22 Invasive procedures or ultrasound used for other purposes often concomitantly result in fetal sex determination. Although the professional community in the United States proscribes sex selection for nonmedical reasons, fetal sex results are nevertheless generally provided to parents on request and accepted as within the scope of parental rights to fetal characteristic information. 23 Medical indications for prenatal sex testing include prevention or management of sex-linked disorders. 24 A male is at 50% risk of inheriting a recessive X-linked condition, such as hemophilia or Duchenne muscular dystrophy, if his mother is a carrier of one affected allele. Currently, recommendations for pregnant carriers of genes for these disorders include invasive testing for the presence of the specific genetic mutation on the X chromosome. 26 Through early noninvasive sex determination using cell-free nucleic acids, women bearing female fetuses can be spared the risks of undergoing further invasive testing and can receive results sooner in pregnancy. 25, 27, 28 Additionally, congenital adrenal hyperplasia (CAH) is a condition affecting both sexes that is characterized by abnormal hormone production. One associated symptom in female fetuses, genital virilization, can be eliminated or reduced with early antenatal dexamethasone therapy, and thus prenatal sex determination is recommended for at-risk pregnancies. 29 Because dexamethasone is not completely effective at preventing virilization, carries unknown risks for pregnant women and fetuses, and does not address the underlying congenital cause of CAH, such that other symptoms of varying severity will still present in treated neonates, the medical community has not reached consensus on the use of this antenatal therapy. 29 Early detection of a male fetus using cell-free fetal nucleic acids can eliminate the unnecessary administration of dexamethasone and any associated risks for male fetuses, and the ability to identify female fetuses earlier in pregnancy allows targeted and early dexamethasone therapy, which may improve its effectiveness. 30 The initial discovery of cell-free fetal DNA in maternal plasma relied on polymerase chain reaction (PCR) amplification and electrophoresis of DSY14, a gene located on the Y chromosome. 6 By this method, fetal DNA is necessarily detected only in blood samples of women bearing male fetuses; however, not all of these women had a detectable concentration of DSY14 and sensitivity in this original research was limited to 80% detection of male-bearing pregnancies. More recently, prenatal sex determination has relied on the detection of SRY, the sex-determining region on the Y chromosome, which may provide more reliable diagnostic capability than DYS14. 31 Laboratory techniques for sex detection have also been improved from combined PCR-electrophoresis to quantitative real-time PCR, which increases throughput and improves accuracy to 97% to 100% in the first trimester of pregnancy. 14, [32] [33] [34] Cell-free fetal DNA sex determination tests using real-time PCR are currently available nearly worldwide. In Europe, tests for sex determination are available as early as 7 weeks of gestation; these tests cost $390 and require a physician referral and sample collection at a clinical laboratory. 35 In contrast, tests from direct-to-consumer companies in the United States and Canada can be provided as a kit via mail to customers in most countries (excluding China and India, where prenatal sex testing is illegal) or in person at specified collection sites. [36] [37] [38] [39] These tests are available starting at a gestational age of 10 weeks and cost between $150 and $390. Although testing accuracy is asserted to be Ͼ95%, questions have been raised over these figures, as direct-to-consumer tests are deemed "laboratory-developed" and thus are exempt from rigorous Food and Drug Administration oversight. 40 A class-action lawsuit filed in 2006 claiming incorrect results from a previously available cellfree fetal DNA sex determination test elucidated the need to better define the roles of commercialization and regulation of this technology.
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Fetal Blood Typing
Fetal sex determination demonstrated that cell-free DNA sequences exclusive to the fetus circulating in maternal blood could provide significant prenatal diagnostic information. Within a year of this finding, comparable techniques were applied to RhD blood group genotyping. RhD blood group incompatibility between a fetus and pregnant woman may result in isoimmunization, hemolytic disease, and miscarriage, but with modern perinatal care including administration of prophylactic anti-RhD immune globulin, negative outcomes are effectively preventable.
In the United Kingdom and other countries, cellfree fetal DNA tests are now routinely being offered to RhD-negative patients at increased risk of isoimmunization, and anti-RhD immune globulin, a blood derivative, is only offered in the event of a RhDpositive fetus for these women. [42] [43] [44] However, in the United States, prophylactic treatment is recommended for all RhD-negative pregnant women to prevent isoimmunization in case of RhD incompatibility, and confirmation that the fetus is RhD-positive is not required. 45 In the United States, amniocentesis still serves as the gold standard diagnostic tool for those women who require antenatal fetal blood genotyping, but it has been suggested that technology using cell-free fetal DNA may ultimately replace this invasive procedure. 46 Widespread adoption of fetal RhD genotyping tests among all RhD-negative patients has the potential to reduce the number of women carrying RhD-negative fetuses who are unnecessarily receiving anti-RhD immune globulin, which is costly, requires plasma donors as its source, and may pose minor risks to the pregnant women. 47 Whether cell-free fetal DNA testing would be suitable to offer to all RhD-negative patients is currently being explored, taking concerns of cost-effectiveness, availability, and reliability into consideration. 48 One analysis suggests that, assuming the current level of accuracy of noninvasive RhD genotyping tests, replacement of anti-RhD prophylaxis administration with testing would, in fact, result in greater risk of sensitization for RhD-negative women. 49 Using a combined PCR-electrophoresis protocol or quantitative real-time PCR technology, similarly as for fetal sex detection, cell-free RHD sequences from an RhD-positive fetus can be detected in the blood of RhD-negative pregnant women. 50, 51 A meta-analysis demonstrates that fetal RhD blood type tests offer overall 95% accuracy and can be performed as early as a gestational age of 8 weeks. 52 In Europe, cell-free fetal DNA tests for RhD genotype, which cost $390, have been commercially available since 2001 and may achieve diagnostic accuracy of 99% when offered at gestational age of 16 weeks or greater. 35, 53 In the United States, a similar product, which combines SRY and RHD tests, is available for $250. 54 Both tests require the referral of a physician, laboratory collection of a maternal blood sample, and a gestational age of 15 or 16 weeks. Development of highthroughput methods for real-time PCR-based genotyping promises to further increase availability and lower costs of these tests. 55 Laboratory techniques other than real-time PCR, such as a combinatory PCR-mass spectrometry (MS) method, are being pursued for their utility in joint sex determination and blood type tests. 56, 57 It has been suggested that high costs and low availability of MS equipment may be prohibitive to widespread clinical implementation of these testing techniques; however, in the United States, cell-free fetal sex determination and RhD genotyping tests using proprietary combined PCR and MS methods were made commercially available in early 2010. 58 Tests must be ordered through a physician and carry a sensitivity and specificity of 97% based on a large-scale validation study. 59 Multiplexed realtime PCR is also being explored for this purpose, as it may afford higher throughput and less potential for contamination. 60, 61 Cell-free fetal DNA tests are also being developed to detect maternal-fetal incompatibilities for other blood types, including RhC, RhE, and Kell (K). Similarly to RhD testing, high accuracy for blood group typing has been achieved using either real-time PCR or PCR-MS, particularly when testing is enhanced by locked nucleic acids. 57, 62 These comprehensive blood typing tests are now available for high-risk pregnancies through a physician referral in Europe, but remain to be introduced in the United States.
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Detecting Single-Gene Conditions
Using principles similar to those for fetal sex and blood type detection, the presence of a sequence in a mother's blood that is not part of the maternal genome may indicate that either the fetus has inherited an allele solely from the father or a de novo mutation has occurred. Detection or absence of such alleles and mutations can aid in the diagnosis or exclusion of single-gene disorders and the identification of HLA haplotypes.
Currently, invasive procedures are the standard of care for detecting severe, child-onset single-gene conditions, and cell-free fetal nucleic acid tests are not yet commercially available. 63 However, research has been undertaken that demonstrates such tests are feasible and may become attainable in the clinical setting. Early studies in detection of single-gene mutations and polymorphisms using cell-free fetal DNA have shed light on the need to increase accuracy and throughput and decrease costs for them to be used clinically in a widespread manner. Existing invasive prenatal tests cost approximately $880 to $1100 and are essentially 100% accurate in detecting singlegene mutations; a test using cell-free fetal DNA, while offering additional benefits of being noninvasive with earlier, broader timing for use, may need to be competitive with invasive tests in these other respects. 64 In 2000, scientists first used cell-free fetal DNA to detect the inheritance of a paternal mutation for a dominant single-gene disorder in a fetus at risk for myotonic dystrophy. 65 Successful identification of this known mutation, given that it did not exist in the maternal DNA, utilized PCR followed by electrophoresis. Follow-up studies using restriction fragment length polymorphism analysis or touchdown or nested PCR demonstrated improved detection of known mutations, such as those for achondroplasia and hemoglobinopathy, by reducing mispriming. [66] [67] [68] Soon after, allele-specific PCR followed by electrophoresis was applied to the diagnosis and exclusion of Hb Lepore disease and Huntington disease; identification of Huntington disease status was demonstrated to be highly accurate as early as 10 weeks of gestational age, although test sensitivity was reduced with greater expansion of CAG trinucleotide repeats (which correspond to greater disease penetrance and earlier age of onset). 65, [69] [70] [71] [72] Similarly, allele-specific real-time PCR has been demonstrated for HLA typing, which may be useful if HLA matching is desired in a fetus for the purpose of hematopoietic stem cell transplantation to an ailing sibling. 73 In addition to detecting disease-causing mutations, real-time PCR for paternally inherited short tandem repeats has also been applied to noninvasive paternity testing. 74 Recessive disorders pose a greater challenge to prenatal diagnosis using cell-free fetal nucleic acids, due to the inability to distinguish between maternal and fetal sequences and thus the uncertainty of fetal inheritance of maternal alleles. Absence of a paternally inherited or de novo mutation in maternal blood permits definitive exclusion of recessive traits. Meanwhile, detection of a mutation demonstrates that the fetus is either a heterozygous carrier or an affected compound heterozygote or homozygote, depending on whether the maternal mutation is identical to paternal mutation. Allele-specific PCR followed by electrophoresis allows detection or exclusion of paternal mutations for recessive conditions, such as CAH and cystic fibrosis, between 11 and 17 weeks of gestational age. 75, 76 Similarly, allelespecific real-time PCR can be applied to mutations for cystic fibrosis and ␤-thalassemia with 100% sensitivity and near-perfect specificity. 77, 78 A unique approach to the diagnosis of recessive diseases in which the mother and father carry the same mutation entails examination of the relative mutation dosage, or the ratio of mutated to wild-type alleles in DNA from maternal blood. 79 Given the equal contribution of wild-type and mutated alleles from a heterozygous mother, the status of fetal inheritance will be dictated by an overrepresentation in maternal blood of the wild-type allele (fetus is unaffected) or mutation (fetus is affected), or a balance of representation of wild-type and mutated alleles (fetus is heterozygous carrier). Similarly, if the mother carries a dominant mutation, predominance of wild-type alleles in maternal blood would imply noninheritance of the condition, whereas balanced wild-type and mutated alleles would represent inheritance of the dominant condition. Specifically, digital real-time PCR, which is more precise than conventional PCR due to individual partitioning of reactions, has been used in this manner to detect inheritance of maternal mutations for thalassemia, hemoglobinopathy, and hemophilia. 79, 80 Theoretically, such analysis could be applied to diagnosis (and not merely exclusion) of recessive diseases with multiple disease-causing alleles, provided the paternal genotype is known, and in cases of unique paternal mutations, the paternal mutation is also tested in maternal blood.
Like with the detection of SRY and RHD, PCR followed by MS provides greater specificity in detection of known, recessive and dominant paternal mutations, including those for ␤-thalassemia and achondroplasia. 56, [81] [82] [83] Again, there may be significant practical barriers to clinical implementation of MS analysis for single-gene disorders, as most laboratories do not possess the expensive equipment required for MS. 58 One mechanism for bringing single-gene and other types of noninvasive tests closer to clinical application is enrichment of fetal DNA or RNA despite predominantly maternal circulating nucleic acids. Because of the discrepancy between the fragment lengths of cell-free fetal and maternal DNA (less than 300 bp and more than 1000 bp, respectively), size fractionation presents one favorable avenues increasing the fetal-to-maternal DNA ratio. 84 Isolation of shorter fragments and thus concentration of fetal DNA using electrophoresis has improved detection of paternally inherited single-nucleotide polymorphisms (SNPs), paternally inherited and de novo mutations, and fetal microsatellite markers; methods using digital PCR for selective amplification of shorter fragments are also being explored. 66, [82] [83] [84] [85] [86] Whole genome amplifica-tion may be a secondary means of counteracting low levels of fetal DNA. 87 An integrated, multistep microsystem based on the principle of size separation has been developed for the purpose of being an easy-to-use and inexpensive clinical option. 88 Alternatively, suppression of wild-type alleles, either in fetal or maternal DNA, and thus improved enrichment of mutated alleles can be achieved by using peptide nucleic acid-mediated PCR to hinder amplification of wild-type sequences.
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Identifying Aneuploidy
Prenatal aneuploidy testing is another potential realm for the application of cell-free fetal DNA technology. Aneuploidy, defined as any abnormal number of chromosomes, affects 1 in 300 newborns and is the most common cause of mental retardation; aneuploidies are also responsible for at least 35% of miscarriages. 90 The most common aneuploidies in live births include trisomy 21 (Down syndrome), trisomy 13, trisomy 18, and monosomy or trisomy of the sex chromosomes, including Turner syndrome and Klinefelter syndrome.
Current standards for aneuploidy detection include preliminary screening to assess risk, and when indicated, subsequent invasive procedures. Recommended screening, which includes first-and second-trimester maternal serum test for specific analytes and a nuchal translucency test by ultrasound, can detect approximately 92% to 96% of cases of trisomy 21; this screening has demonstrated similar, if not higher, detection rates for other aneuploidies. 91, 92 False-positive rates are typically approximately 5%. The American College of Obstetricians and Gynecologists recommends that all women, including those with increased risk based on screening results, should be offered invasive diagnostic testing. 93 As described for other uses of invasive tests, these procedures offer essentially definitive diagnoses for aneuploidy, but carry a 1% to 2% risk of miscarriage and are only available during specific gestational windows. 21 The cost of screening is roughly $100 to $370 in addition to the high costs of invasive tests when indicated; screening and diagnostic tests are typically covered by insurers in the United States. 64, 94 If cell-free fetal nucleic acid testing for aneuploidy was to become commercially available, its role in the existing structure of prenatal screening and testing would largely be contingent on its reliability, costs, and feasibility for wide-scale implementation. 42 Currently, it is estimated that sequencing-based noninvasive aneuploidy testing may cost more than $700 to $1200 per case and that only 16 samples can be processed per machine per week, although cost and throughput are rapidly improving; PCR methods may cost significantly less while requiring more rigorous analytic standards to achieve equivalent accuracy. 95, 96 Hypothetical functions for cell-free fetal DNA testing include as an additional component to screening, as a replacement of either screening or diagnostic invasive testing, as a replacement for both screening and diagnostic testing, or as an intermediate between screening and diagnosis to reduce the number of invasive procedures. 96 Several cell-free fetal DNA and RNA technologies are under development to test a pregnancy for aneuploidy, mostly focusing on Down syndrome testing. These include either directly comparing the total concentration of the chromosome in question with that which is expected based on the concentration of an unaffected chromosome, or by determining the ratio of maternally inherited to paternally inherited alleles on the affected chromosome. By the first method, one would expect a fetus with trisomy to have a 3:2 relative chromosome dosage of affected to unaffected chromosomes. By the second, a trisomic fetus would have a 2:1 allelic imbalance favoring either maternally or paternally inherited alleles. The advantage of using a chromosome dosage method over an allelic balance method is due to its polymorphismindependent nature. With the latter, the presence of an allele inherited from the father, but not the mother, or vice versa, is necessary to determine allelic balance, and the identification of such an allele is not always possible or convenient. 42 Thus, these methods of allelic ratio determination have been ineffective in instances of fetal homozygosity. Moreover, as fetal DNA exists in reduced concentration relative to maternal DNA, analysis using specific alleles makes use of only a small subset of DNA; a significant problem confronting this research entails the development of effective analytic methods despite low fetal DNA concentrations.
Proof of concept for differential epigenetic signatures of fetal and maternal DNA was demonstrated in the unique methylation patterns of some fetal SNPs and led to the first use of allelic ratio for aneuploidy detection. Specifically, the placental maspin gene promoter on chromosome 18 is hypomethylated relative to the densely methylated maternal promoter. 17 These differences in methylation can be exploited to assess fetal DNA concentration; shortly after this discovery, researchers demonstrated proof of principle for diagnosis of trisomy 18 via maspin allelic ratio using methylation-specific PCR. 97, 98 As differ-ent alleles are necessary to determine allelic ratio, this method could not be applied in cases of fetal homozygosity. More recent studies have continued to search for other fetal DNA markers based on epigenetic modification. [99] [100] [101] Evidence for successful determination of allelic balance for a chromosome 18 gene led to analysis of chromosome 21 SNPs, including those on PLAC4 mRNA, which is expressed exclusively in the placenta, to detect Down syndrome. 18, 102 For fetuses heterozygous for a specific PLAC4 SNP, identification of trisomy 21 by allelic imbalance using reverse transcription PCR and MS attained 90% sensitivity and 97% specificity. A similar technique was applied to a set of 5 SNP loci on PLAC4, attaining 92% sensitivity and 100% specificity, and may represent a higher-throughput, more widely applicable use of PLAC4 SNP analysis. 103 In both instances, fetal homozygosity precluded aneuploidy detection. However, more generally, this success in using mRNA to detect aneuploidy stimulated the proliferation of research on placenta-originating mRNA in attempts to discover novel universal fetal genetic markers for broader prenatal diagnostic purposes. 104 Aneuploidy detection by allelic imbalance was next explored using digital PCR, chosen to improve quantification sensitivity and based on earlier proof of principle using amniocyte samples. 105, 106 Using an SNP on PLAC4 to determine allelic balance for chromosome 21, classification of aneuploid and euploid fetuses reached 100% accuracy, although with a small sample size. One of these samples required further testing beyond the initial plate; due to the predominance of maternal DNA in real samples, calculations suggest approximately 3% of cases will require such follow-up analysis for a conclusive diagnosis to be made.
This same study also demonstrated the first use of relative chromosomal dosage to detect aneuploidy. 105, 106 By examining the ratio of concentrations of nonpolymorphic loci on chromosomes 1 and 21, this polymorphism-independent method proved 100% accurate. However, between 1 and 7 plates were required for each conclusive diagnosis, thus making digital PCR in this form labor-intensive. A follow-up study quickly confirmed the precision of digital PCR in relative chromosomal dosage and thus aneuploidy detection while highlighting the need for extensive analyses in light of low ratios of fetal DNA to maternal DNA. 107 Massively parallel genomic sequencing was introduced to address previous concerns of the preponderance of maternal DNA over fetal DNA while achieving the desired precision of digital PCR. 108, 109 Although PCR depends on select loci only present on some DNA fragments, massively parallel sequencing can be used in both a polymorphism-independent and loci-independent manner to take advantage of all DNA fragments in a sample. By simultaneously sequencing all or even targeted fragments, aligning the sequences to their respective chromosomes, and quantifying each chromosomal dosage, issues surrounding predominance of maternal DNA can be resolved even with markedly smaller sample sizes. 110 Proof of principle studies demonstrated 100% accurate detection of chromosomal overrepresentation in instances of trisomies 13, 18, and 21. 108, 109 Follow-up studies indicate that sensitivity to aneuploidy or mosaicism is constrained only by sequencing depth: that is, the greater the number of sample reads, the greater the detection of over-or under-representation of any complete or partial chromosomal anomaly. 111 Massively parallel genomic sequencing may also provide a means to detect trisomy caused by other cytogenetic anomalies, such as Robertsonian translocations. 112 In fact, due to its successes, the technique of massively parallel genomic sequencing may be the first to realize clinical application. A recent study of 753 pregnancies has demonstrated 100% sensitivity and 98% specificity for detection of trisomy 21 using multiplexed sequencing, while suggesting the technique's applicability to other chromosomal aneuploidies and mosaicisms; these detection rates are comparable with existing screening, but not with diagnostic tests. 96, 113 A second trial was completed by an independent biotechnology company and resulted in 100% sensitivity and 99.7% specificity of trisomy 21. 114 Most recently, a third trial by a different company demonstrated that by using sequencing, trisomy 18 and other chromosomal abnormalities could also be detected, and that these methods were informative in twin gestations. 115 An alternative strategy for aneuploidy detection uses tandem SNPs to bypass concerns of maternal DNA predominance while avoiding high costs associated with sequencing methods. 116 Tandem SNPs are 2 highly heterozygous, neighboring polymorphisms that allow for 4 possible haplotype permutations. If a mother expresses 2 different haplotypes and the father carries at least 1 additional distinct haplotype, the dosage of each haplotype in maternal plasma will be informative for the fetal haplotype. In cases of trisomy, a fetus will have either 3 haplotypes or an imbalance of 2 haplotypes, depending on when nondisjunction occurred. In addition to a preliminary specificity and sensitivity of 100%, this technique has the added benefits of usability through a number of PCR or sequencing platforms and applicability to a range of chromosomal aberrations; however, a significant proportion of cases will not be informative for a given tandem SNP.
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Mapping the Whole Genome
Until recently, certain genetic conditions have presented methodological complications intractable to existing analytic methods. Because of the fragmented state of cell-free fetal DNA, any disease-causing sequences longer than 300 base pairs have not been detectable with these methods. 86, 117 Additionally, by virtue of the difficulties in distinguishing between identical maternally and paternally inherited alleles in fetal DNA, efforts at prenatal detection of recessive disorders caused by a single mutation, such as sickle cell anemia, have been minimal.
Previously reported MS analysis of admixed maternalfetal DNA despite identical maternal and paternal diseasecausing mutations suggested a means to avoid this limitation; by analyzing the maternal and paternal haplotypes and seeking informative paternal SNPs linked to the mutation, fetal inheritance of the paternal SNP and thus haplotype allowed deduction of fetal ␤-thalassemia status. 81 More recent work has demonstrated that similar techniques can be broadened to the entire fetal genome using haplotype dosage, similarly to allelic balance or chromosome dosage techniques. 19, 20, 79, 106 By obtaining both the maternal haplotype and paternal genotype and then sequencing DNA in the maternal plasma, determination of fetal inheritance blocks can be performed through deductive statistical analysis. These blocks can then be assembled into a map of the entire fetal genome with sensitivity between 95.5% and 99.5%.
Hurdles to the clinical implementation of prenatal genome mapping include high cost and low throughput of sequencing platforms, requirement of complex statistical methods, and currently limited knowledge of haplotype information. For diagnosis of disease in at-risk populations, these barriers may be avoided through targeted searches for known disease-causing regions. Overall, ascertainment of the whole fetal genome is possible and ultimately, with further development and support, likely to be introduced into the clinical sphere.
Predicting Pregnancy Complications
Cell-free fetal nucleic acids may also serve an important role in perinatal care, as the concentration of circulating DNA has predictive capabilities for pregnancy complications. Most notably, the severity of proteinuria and hypertension, the 2 major symptoms of preeclampsia, is associated with increased concentrations of cell-free fetal DNA. 118, 119 This elevation of cell-free fetal DNA levels typically precedes the onset of preeclampsia, offering potential identification of at-risk pregnancies.
120,121 Elevated cell-free fetal DNA levels have also been noted in pregnant women with invasive placenta, hyperemesis gravidarum, and preterm labor. [122] [123] [124] This type of quantitative analysis is typically accomplished by determining concentrations of Y-specific sequences circulating in the blood of women bearing male fetuses divided by concentrations of a marker of total cell-free DNA, like ␤-globin or GAPDH, to calculate the amount of DNA derived specifically from the fetus. 125, 126 Alternative methods include measuring concentrations of other fetal genetic markers, such as PLAC1, CRH, and selectin-P mRNA, for femalebearing pregnancies. [127] [128] [129] [130] As researchers continue to search for fetal DNA or RNA indicators for pregnancy complications, it is plausible that new universal markers for fetal-specific genetic sequences in maternal blood will be discovered that will be valuable for use in other applications of noninvasive prenatal testing.
Conclusion and Future Directions
The discovery of cell-free fetal DNA and RNA circulating in the maternal bloodstream has opened the door to noninvasive genome-wide prenatal testing with novel clinical implications. Applications of cell-free fetal DNA testing currently available include fetal sex determination and RhD typing, offered through government agencies and direct-toconsumer companies. Moreover, the range of fetal genetic traits that can be identified using this technology seems to be constrained only by our knowledge of genomics, and indeed, applications such as detection of aneuploidies and paternally inherited or de novo mutations are close on the horizon. As scientific research and development of cell-free fetal DNA and RNA technology is advanced, this testing may gradually supersede or supplement existing screening and diagnostic procedures.
Although current use in the clinical setting is minimal, this technology has demonstrated potential to significantly change prenatal genetic testing because of its noninvasiveness, broad indications, and earlier timing for use. However, such changes would not come without substantial ethical, legal, and social concerns, which will largely depend on which role cell-free fetal nucleic acid testing assumes in the existing menu of prenatal tests. Some essential questions raised by technology using cell-free fetal DNA and RNA include patenting and intellectual property; regulation of validity and clinical utility; third-party payment availability, and access, and, in particular, the potential for direct-to-consumer testing; definition and provision of satisfactory informed consent; provider and patient values and decision making, especially with regard to termination of pregnancy; and personal and societal consequences of diagnosis or prediction of fetal traits, and particularly traits of little or no medical significance. 96, [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] Existing literature lacks a thorough and comprehensive assessment of the attitudes and priorities of stakeholders in this technology, who may represent both its early adopters and its critics. These individuals and institutions may include, but are not limited to, scientists, funders of research, prospective patients and their families, healthcare providers, insurers, the disability rights community, and society at large. Assessment and alignment of the values of all stakeholders will be necessary to the successful translation of cell-free fetal DNA and RNA technology.
